Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.

British journal of cancer - 16 Dec 2008

Nakayama N, Nakayama K, Yeasmin S, Ishibashi M, Katagiri A, Iida K, Fukumoto M, Miyazaki K

Abstract excerpt

This study examined the status of KRAS and BRAF mutations, in relation to extracellular signal-regulated protein kinase (ERK) activation in 58 ovarian carcinomas to clarify the clinicopathological and prognostic significance of KRAS/BRAF mutations. Somatic mutations of either KRAS or BRAF were identified in 12 (20.6%) out of 58 ovarian carcinomas. The frequency of KRAS/BRAF mutations in conventional serous...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Enzyme Activation
Share to Mice, Nude
Share to Mitogen-Activated Protein Kinase 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mitogen-Activated Protein Kinase 3

Share to Mitogen-Activated Protein Kinase Kinases

Share to ras Proteins

Share to Survival Rate

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 19018267
DOI: 10.1038/sj.bjc.6604783
PMCID: PMC2607229

Genes

BRAF
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.PMID 19018267Read ↗

Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations.Semantic proximity Read ↗

Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic targetSemantic proximity Read ↗

KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.Semantic proximity Read ↗

The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis.Semantic proximity Read ↗

Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.Semantic proximity Read ↗

Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.Semantic proximity Read ↗

The ERK inhibitor GDC-0994 selectively inhibits growth of BRAF mutant cancer cellsSemantic proximity Read ↗

KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.Semantic proximity Read ↗

Comparative study of BRAF gene mutations in ovarian serous tumors by immunohistochemistry and DNA sequencing.Semantic proximity Read ↗

Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on KRAS/NF1 Mutational Status.Semantic proximity Read ↗

P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas.Semantic proximity Read ↗

Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.